CLAIMS

1) A composite containing a drug dispersed in an organic carrier selected from a complexing agent or a cross-linked polymer and mixtures thereof, wherein the drug is massively dispersed (in-bulk) within the composite, and is present in amorphous form in a quantity greater than or equal to 50 % by weight, with respect to the total of drug present in the composite.

2) The composite according to claim 1, in which the drug and the carrier are present in weight ratios comprised of between 1:0.5 and 1:20.

3) The composite according to claim 2, in which the drug and the carrier are present in weight ratios comprised of between 1:1 and 1:10.

4) The composite according to claims 1-3, in which the cross-linked polymer is selected from cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene, cross-linked β-cyclodextrine.

5) The composite according to claims 1-4, in which the complexing agent is selected from alpha-cyclodextrine, beta-cyclodextrine, gamma-cyclodextrine, derivatives thereof, maltodextrine.

6) The composite according to claims 1-5, in which said organic carrier has a surface area comprised of between 0.05 m^2/g and 20 m^2/g.

7) The composite according to claims 1-6, in which said drug is a drug sparingly soluble in water.

8) The composite according to claim 7, in which said drug is selected from nimesulide, ibuprofen, nifedipine, grisofulvine, piroxicam, progesterone, lorazepam.

9) The composite as described in the claims 1-8, for use in therapy.

10) A pharmaceutical composition containing the composite described in claims 1-8, optionally associated with pharmaceutically acceptable excipients.

11) The pharmaceutical composition according to claim 10, formulated as a granulate, pill, mini-pill, capsule, micro-capsule.

12) A process for the preparation of the composite described in claims 1-8, comprising the following steps:
a) forming a wet mixture of said drug and said organic carrier;
b) irradiating the mixture obtained in a), with microwaves such that the mixture is heated to a temperature higher than the melting temperature of the drug, and such temperature is thus maintained for at least 5 minutes.

13) The process according to claim 12, in which said wet mixture is formed by adding water to the carrier-drug composite in a quantity comprised of between 0.1 ml/g and 5 ml/g with respect to the dry mixture of the composite.

14) The process according to the claims 12-13, in which the pressure at which the irradiation is carried out is comprised of between 1 and 20 bar.

15) The process according to the claims 12-14, in which the irradiation with microwaves is carried out in an power range comprised of between 100 W and 5000 W for an overall time up to 120 minutes.

16) A process for the preparation of the composite described in the claims 1-8, comprising the following steps:
a) mixing together said drug and said organic carrier;
b) placing the mixture obtained in a) in a container constituted of a dielectric material having coupling capacity with the microwaves;
c) irradiating with microwaves the container containing said mixture, such that the

mixture is heated to a temperature higher than the melting temperature of the drug, and such temperature is maintained for at least 5 minutes.

17) The process according to claim 16, in which said dielectric material is polytetrafluoroethylene loaded with graphite.

18) The process according to the claims 16-17, in which the irradiation with microwaves is carried out in an power range comprised of between 100 W and 5000 W, for an overall time up to 120 minutes.

19) A composite obtainable through the process described in the claims 12-18.